VPIX Medial and SKIA recognized for their novel approaches to surgicial oncology with applications that aim to provide ‘real-time’ advancements in tumor resection
SEOUL, KOREA, October 7, 2021 - Johnson & Johnson Medical Korea Ltd. and Johnson & Johnson Innovation LLC today, in collaboration with the Seoul Metropolitan Government (SMG) and Korea Health Industry Development Institute (KHIDI), named VPIX Medical and SKIA as awardees of the Seoul Innovation QuickFire Challenge on Smart Surgery.
VPIX Medial and SKIA will receive a combined total of KRW150,000,000 in grant funding, residency at the Seoul Bio Hub, access to Johnson & Johnson Innovation's Asia Pacific ecosystem including a dedicated workstation for one year at JLABS @ Shanghai, and mentorship from experts across the Johnson & Johnson Family of Companies.
- VPIX Medical: VPIX Medical is developing cCeLL, a fluorescence confocal endomicroscope for real-time digital biopsy. cCeLL aims to enable rapid decision making for resection of cancer by reducing sampling errors, with the goal of improving patient prognosis by shortening the surgical time required by conventional frozen tissue tests.
- SKIA: SKIA aims to provide a digital surgery guide solution using augmented reality (AR) technology for superimposing a patient's medical images (e.g., CT or MRI) over a real-time camera view of the patient, by which surgeons can accurately locate tumor resection sites.
“The Asia Pacific healthcare ecosystem has an affinity for cutting edge health technology,” said Melinda Richter1 , Global Head, Johnson & Johnson Innovation – JLABS. “While past QuickFire Challenges in the Seoul Innovation series have sought to advance novel ideas in areas of focus such as robotic surgery and healthcare for the new normal, in our fifth QuickFire Challenge in Seoul, we sought to uncover and champion potential breakthrough ideas aiming to improve surgicial patient care.”
The challenge invited visionaries to submit novel ideas with the potential to transform the surgical pathway for optimized care, cost savings, and improved patient outcomes. Specific areas of interest included:
- Potential digital solutions that aim to help OR transform surgical pathway/ data-driven decisions (before, during, and after surgery)
- Smart diagnosis and early intervention in cardiovascular and neurovascular areas.
- Infection control during and after surgery.
- Potential biotech solutions aiming to improve post-op recovery.
- Improved surgical planning and outcome using next-gen technology (including but not limited to advancing imaging and AR).
"The need to optimize surgical care and improve patient outcomes has sparked transformative innovation, which was apparent in the strength of applications we received for this challenge,” said Young Joo Song2, Sr. Director of Government Affairs, Johnson & Johnson Medical Korea. “Johnson & Johnson Innovation looks forward to working with VPIX Medial and SKIA with the aim to help nurture their digitally-enabled potential solutions in surgical oncology."
The Seoul Innovation QuickFire Challenge aims to help advance breakthrough ideas for healthcare solutions by combining Johnson & Johnson Innovation's unique vision for collaboration with the Seoul Metropolitan Government's efforts to drive innovation and commercialize its research outcomes; KHIDI's professional and systems-building support; and the Seoul Bio Hub's ability to help accelerate the development and commercialization of potential early-stage life science solutions.
VPIX Medial and SKIA join eight previous Seoul Innovation QuickFire Challenges awardees named annually between 2017 through 2021.
For more information about the QuickFire Challenges, please visit:
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.
About Johnson & Johnson Medical Devices
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to the award announcement of the Seoul Innovation QuickFire Challenge on Smart Surgery. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation LLC, Johnson & Johnson Medical Korea Ltd and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson Innovation LLC, Johnson Medical Korea Ltd and/or Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
Johnson & Johnson Innovation LLC:
+86 139 1171 2835